Successful treatment of trichilemmal carcinoma with distant metastasis using pembrolizumab: a case report and review

4Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Trichilemmal carcinoma (TC) is a rare, malignant cutaneous adnexal tumor. TC often has nonspecific clinical manifestations and its aggressive nature is frequently overlooked. Metastasis of TC is rarely reported and there is no standard treatment for recurrent or metastatic TC. We report a complicated case of TC arising from the parotid gland with metastasis to cervical lymph nodes. The tumor progressed after multiple surgeries, radiation and chemotherapy. Finally, the patient achieved good response and disease control with pembrolizumab, an immune checkpoint inhibitor targeting programmed cell death protein-1. Currently, the patient has received 19 cycles of pembrolizumab and the disease remains well controlled. This represents the first reported use of immune checkpoint blockade to treat TC.

Cite

CITATION STYLE

APA

Liu, L., Long, T., Wei, N., Zhang, H., Tang, C., & Gao, J. (2024). Successful treatment of trichilemmal carcinoma with distant metastasis using pembrolizumab: a case report and review. Immunotherapy, 16(10), 659–667. https://doi.org/10.1080/1750743X.2024.2353535

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free